EC Pulmonology and Respiratory Medicine

Editorial Volume 14 Issue 8 - 2025

From Scarcity to Opportunity: Rethinking Lung Donation, Technology, and Access in the U.S. Transplant System

Jenks Christopher*

Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA

*Corresponding Author: Jenks Christopher, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA.
Received: July 09, 2025; Published:July 16, 2025



Lung transplantation remains a critical but constrained treatment option for individuals suffering from end-stage respiratory illnesses, including chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, and pulmonary arterial hypertension. In the United States, while thousands of patients are added to the transplant list annually, the number of lungs suitable for transplantation is severely limited. Many of the donated lungs are ultimately discarded before use, often due to concerns over organ quality or logistical limitations [1]. This issue is further compounded by the narrow criteria used to define “ideal” donor lungs, criteria met by only 10 - 20% of potential donors. These include characteristics such as non-smoking history, normal chest imaging, and adequate oxygenation levels [2,3]. Consequently, a significant proportion of potentially transplantable lungs are excluded from consideration early on, despite evidence suggesting many could function well if reassessed using modern technologies.

  1. Valapour M., et al. “OPTN/SRTR 2020 annual data report: lung”. American Journal of Transplantation 2 (2022): 438-518.
  2. Orens JB., et al. “A review of lung transplant donor acceptability criteria”. Journal of Heart and Lung Transplantation 11 (2003): 1183-1200.
  3. Mody S NS., et al. “Lung donor selection and management: An updated review”. OBM Transplantation4 (2023): 203.
  4. Cypel M., et al. “Normothermic ex vivo lung perfusion in clinical lung transplantation”. New England Journal of Medicine 15 (2011): 1431-1440.
  5. Warnecke G., et al. “Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study”. Lancet Respiratory Medicine5 (2018): 357-367.
  6. Neizer H., et al. “Addressing donor-organ shortages using extended criteria in lung transplantation”. Annals of Cardiothoracic Surgery 1 (2020): 49-50.
  7. National Academies of Sciences E, and Medicine. Realizing the Promise of Equity in the Organ Transplantation System. Kenneth W. Kizer RAE, and Meredith Hackmann, editor. Washington, DC: The National Academies Press (2022).
  8. Siminoff LA., et al. “Factors influencing families' consent for donation of solid organs for transplantation”. Journal of the American Medical Association 1 (2001): 71-77.
  9. Mooney JJ., et al. “Racial and ethnic disparities in lung transplant listing and waitlist outcomes”. Journal of Heart and Lung Transplantation 3 (2018): 394-400.
  10. Alachraf K., et al. “Trends in racial and ethnic disparities in pediatric lung transplantation in the United States”. Pediatric Pulmonology 12 (2024): 3204-3211.
  11. Purnell TS., et al. “Association of race and ethnicity with live donor kidney transplantation in the United States from 1995 to 2014”. Journal of the American Medical Association 1 (2018): 49-61.

Jenks Christopher. "From Scarcity to Opportunity: Rethinking Lung Donation, Technology, and Access in the U.S. Transplant System". EC Pulmonology and Respiratory Medicine  14.8 (2025): 01-03.